We’re proud of our lineage.
In the late 1990’s, Dr. David Euhus and UT Southwestern developed the initial version of CancerGene to aid in the diagnosis and cancer risk assessment of patients based on the leading algorithms available.
With CancerGene, clinicians were now able to quickly and digitally run complex risk assessment algorithms that previously required laborious research calculations for every patient. The improvements that CancerGene provided, as well as the accuracy and power of the tool, led to it quickly becoming the institutional standard used throughout the academic and research world. By the early 2000's, over 4,000 institutions relied on CancerGene.
In the early 2000’s, cancer risk assessment began to extend beyond research institutions and become part of the normal care within hospitals and individual practices. This integration with the general population meant a significant effort was required to gather and diagram family histories in order to run the assessments. Dr. Euhus and UT Southwestern wanted to integrate these collection and organization steps into the process and in 2009 released the end-to-end solution now known as CancerGene Connect.
By encouraging family history collection by the patients prior to their genetics appointment, CancerGene Connect allowed for a more thorough and detailed accounting of information in an environment much more suited for these personal questions. Allowing patients the time to connect with other family members to collect specific details elevated the quality of the data significantly. As a by-product, this approach means clinicians can spend much more time engaging with each and every patient in meaningful ways.
The power of CancerGene Connect has not gone unnoticed. In 2013, UT Southwestern won the prestigious Innovator Award from the Association of Community Cancer Centers (ACCC) for its work on CancerGene Connect and the number of patients receiving assessments continued to grow dramatically.
In 2014, UT Southwestern published the results of a 5-year study focused on the impact of CancerGene Connect on the cancer genetics clinic. That study demonstrated that the software platform had allowed nearly twice as many patients to be seen by genetic counselors as before. Notably, each patient still received the same amount of time and attention, with that attention now being spent on risk assessment and counseling instead of data gathering.
Today, CancerGene Connect continues an aggressive trajectory of upgrades and refinements that will continue to improve the efficiency and power of our assessment platform.